伊立替康联合氟尿嘧啶、亚叶酸钙二线治疗晚期结直肠癌的临床观察  

Clinical Observation of Irinotecan in Combination of Fluorouracil and Calcium Folinate as A Second Line Treatment for Advanced Colorectal Cancer

作　　者：曾继泽[1] 周航[1] 刘霄[1] 

机构地区：[1]遵义医学院附属医院肿瘤医院二病区,遵义市563003

出　　处：《中国药房》2008年第23期1812-1813,共2页China Pharmacy

摘　　要：目的:观察FOLFIRI方案二线治疗晚期结直肠癌的疗效及安全性。方法:28例FOLFOX4化疗失败的患者,改用FOLFIRI方案挽救化疗。结果:完全缓解为0例,部分缓解6例,稳定16例,进展6例,有效率21.4%。不良反应主要为恶心、呕吐、白细胞减少和延迟性腹泻。结论:FOLFIRI方案二线治疗晚期结直肠癌,疗效肯定,不良反应可控制。OBJECTIVE： To observe the clinic efficacy and safety of FOLFIRI as a second line treatment for patients with advanced colorectal cancer. METHODS： Twenty - eight patients with advanced colorectal cancer whose disease progressed after first treatment with FOLFOX4 were included to receive the second line treatment with FOLFIRI regimen. RESULTS： Of the total 28 cases, 0 had complete response, 6 partial response, 16 stable disease, 6 progressive disease, and the responsive rate was 21.4%. The majority of adverse reaction was nausea, vomiting, leucopenia and tardive diarrhea. CONCLUSION： As a second line therapy, FOLFIRI has a confirmed therapeutic response and tolerable toxicity in patients with advanced colorectal cancer.

关 键 词：伊立替康 氟尿嘧啶 亚叶酸钙 晚期结直肠癌 化学治疗 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]